^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + nelitolimod (SD-101) (TLR9 agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Evaluation of intra-tumoral (IT) SD-101 and pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: Results from the I-SPY 2 trial
Published date:
05/20/2021
Excerpt:
Treatment included weekly P x 12 in combination with IT SD-101 2 mg/ml (1 ml for T2 tumors, 2 ml for >T3 tumors) weekly x 4, then q3 weeks x 2, and IV Pb q3 weeks x 4, followed by doxorubicin/cyclophosphamide (AC)...the rate of pCR/Residual Cancer Burden 1 (RCB1) in the HR+/HER2- signature was 51%....pCR/RCB 1 analysis suggests improved response in the HR+/HER-negative signature compared to control.
Secondary therapy:
AC + paclitaxel
DOI:
10.1200/JCO.2021.39.15_suppl.508
Trial ID:
